...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates.
【24h】

Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates.

机译：在非人灵长类动物的异源初免-加强环境中用重组麻疹疫苗载体引发T细胞反应。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Licensed live attenuated virus vaccines capable of expressing transgenes from other pathogens have the potential to reduce the number of childhood immunizations by eliciting robust immunity to multiple pathogens simultaneously. Recombinant attenuated measles virus (rMV) derived from the Edmonston Zagreb vaccine strain was engineered to express simian immunodeficiency virus (SIV) Gag protein for the purpose of evaluating the immunogenicity of rMV as a vaccine vector in rhesus macaques. rMV-Gag immunization alone elicited robust measles-specific humoral and cellular responses, but failed to elicit transgene (Gag)-specific immune responses, following aerosol or intratracheal/intramuscular delivery. However, when administered as a priming vaccine to a heterologous boost with recombinant adenovirus serotype 5 expressing the same transgene, rMV-Gag significantly enhanced Gag-specific T lymphocyte responses following rAd5 immunization. Gag-specific humoral responses were not enhanced, however, which may be due to either the transgene or the vector. Cellular response priming by rMV against the transgene was highly effective even when using a suboptimal dose of rAd5 for the boost. These data demonstrate feasibility of using rMV as a priming component of heterologous prime-boost vaccine regimens for pathogens requiring strong cellular responses.
机译：能够表达其他病原体转基因的许可减毒活疫苗具有通过同时激发多种病原体强大免疫力来减少儿童免疫接种次数的潜力。为了评估rMV作为恒河猴的疫苗载体的免疫原性，将来自Edmonston Zagreb疫苗株的重组减毒麻疹病毒（rMV）工程化以表达猿猴免疫缺陷病毒（SIV）Gag蛋白。单独的rMV-Gag免疫可引起强烈的麻疹特异性体液和细胞应答，但在气雾剂或气管内/肌内递送后未能引起转基因（Gag）特异性免疫应答。但是，当作为初次接种疫苗与表达相同转基因的重组腺病毒血清型5进行异源加强免疫接种时，rMV-Gag显着增强了rAd5免疫后的Gag特异性T淋巴细胞应答。 gag特异性的体液反应没有增强，但这可能是由于转基因或载体引起的。即使使用次最佳剂量的rAd5进行增强，rMV对转基因的细胞应答引发也非常有效。这些数据表明，对于需要强烈细胞应答的病原体，将rMV用作异源初免-加强疫苗接种方案的引发组分是可行的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号